← Mechanisms of action
T cell surface glycoprotein CD3
PROTEIN COMPLEXHomo sapiens
Linked proteins
Drugs acting on this target (15)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| tebentafusp (Kimmtrak) | Activator | approved | Recombinant protein | T cell surface glycoprotein CD3 activator |
| Elranatamab (Elrexfio) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| Epcoritamab (Epkinly) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| Flotetuzumab | Binding agent | experimental | mAb | T cell surface glycoprotein CD3 binding agent |
| glofitamab (Columvi) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| mosunetuzumab (Lunsumio) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| regn1979 | Binding agent | experimental | mAb | T cell surface glycoprotein CD3 binding agent |
| Talquetamab (Talvey) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| tarlatamab (IMDELLTRA) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| teclistamab (Tecvayli) | Binding agent | approved | mAb | T cell surface glycoprotein CD3 binding agent |
| blinatumomab (blincyto) | Cross-linking agent | approved | mAb | T cell surface glycoprotein CD3 cross-linking agent |
| catumaxomab (Removab) | Cross-linking agent | experimental | mAb | T cell surface glycoprotein CD3 cross-linking agent |
| fbta05 | Cross-linking agent | experimental | mAb | T cell surface glycoprotein CD3 cross-linking agent |
| foralumab | Inhibitor | experimental | mAb | T cell surface glycoprotein CD3 inhibitor |
| muromonab cd3 (Orthoclone OKT3) | Inhibitor | approved | mAb | T cell surface glycoprotein CD3 inhibitor |